Membrane breakdown in acute and chronic neurodegeneration: Focus on choline-containing phospholipids

Journal of Neural Transmission

Volumn 107, Issue 8-9, 2000, Pages 1027-1063

  Klein, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Choline; Glycerophosphocholine; Membrane breakdown; Phosphatidylcholine; Phospholipase A2; Phospholipids

Indexed keywords

AMYLOID BETA PROTEIN; CHOLINE; CHOLINESTERASE INHIBITOR; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PHOSPHORUS 31; PHOSPHORYLCHOLINE;

ALZHEIMER DISEASE; AUTOPSY; BRAIN TISSUE; CEREBROSPINAL FLUID ANALYSIS; CHOLINERGIC NERVE CELL; DEGENERATIVE DISEASE; GENOTYPE; HUMAN; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ACUTE DISEASE; ANIMAL; CELL MEMBRANE; CHRONIC DISEASE; HUMAN; NEURODEGENERATIVE DISEASES; PHOSPHATIDYLCHOLINES;

EID: 0033791814     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020070051     Document Type: Review

References (231)

1. 2
2. Beta-amyloid induced increase in choline flux across PC12 cell membranes
3. + depolarization on choline kinase and choline acetyltransferase activities in superior cervical sympathetic ganglia excised from rats
4. The arteriovenous difference of choline across the brain of man
5. How is membrane phospholipid biosynthesis controlled in neural tissues?
6. β-Amyloid peptides as direct cholinergic neuromodulators: A missing link?
7. Differential effect of CDP-choline on brain cytosolic choline levels in younger and older subjects as measured by proton magnetic resonance spectroscopy
8. 2
9. Increased glycerol-3-phosphorylcholine in post-mortem Alzheimer's brain
10. Arachidonic acid induces a prolonged inhibition of glutamate uptake into glial cells
11. Acute stroke: Evaluation with serial proton MR spectroscopic imaging
12. Effects of ischemia and electroconvulsic shock on free fatty acid pool in the brain
13. Mediators of injury in neurotrauma: Intracellular signal transduction and gene expression
14. Cerebral ischemia: Changes in brain choline, acetylcholine, and other monoamines as related to energy metabolism
15. Cerebral ischemia in young and adult gerbils: Effects on cholinergic metabolism
16. 31P magnetic resonance spectroscopy reveals osmotic and metabolic disturbances in human hepatic encephalopathy
17. Choline, a vital amine
18. Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brais of Alzheimer's disease but not of Down's syndrome patients
19. 2
20. Alzheimer dementia: Quantification of energy metabolism and mobile phosphoesters with P-31 NMR spectroscopy
21. 2, and secretion of catecholamines from brain synaptosomes by potassium and A23187
22. Lipid abnormalities in the brain in adult Down's syndrome and Alzheimer's disease
23. 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia
24. A one-dimensional (proton and phosphorus) and two-dimensional (proton) in vivo NMR spectroscopic study of reversible global cerebral ischemia
25. 31P NMR detection of mobile dog brain phospholipids
26. A randomized dose-response trial of citicholine in acute ischemic stroke patients
27. 2 after transient global forebrain ischemia in the rat
28. Decreased brain choline uptake in older adults
29. Analysis of the water-soluble products of phosphatidylcholine breakdown by ion-exchange chromatography
30. Phospholipid abnormalities in early Alzheimer's disease
31. A simple, sensitive, and economic assay for choline and acetylcholine using HPLC, an enzyme reactor, and an electrochemical detector
32. Neither short-term nor long-term administration of oral choline alters metabolite concentrations in human brain
33. 2
34. Mammalian lysophospholipases
35. Phospholipid signalling
36. Formation of free choline in brain tissue during in vitro energy deprivation
37. Insulin inhibits changes in the phospholipid profiles in sciatic nerves from streptozocin-induced diabetic rats: A phosphorus-31 magnetic resonance study
38. Concentration and origin of choline in the rat brain
39. NMDA receptors activate the arachidonic acid cascade system in striatal neurons
40. The choline-leakage hypothesis for the loss of acetylcholine in Alzheimer's disease
41. Choline levels are increased in cerebrospinal fluid of Alzheimer patients
42. Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease and Huntington's disease
43. 2 activation influences the processing and secretion of the amyloid precursor protein
44. Elevated frontal lobe cytosolic choline levels in minimal or mild AIDS dementia complex patients: A proton magnetic resonance spectroscopy study
45. Enhancement of brain choline levels by nicotinamide: Mechanism of action
46. 2 inhibitor, quinacrine, reduces infarct size in rats after transient middle cerebral artery occlusion
47. Phospholipase D: Enzymology, mechanisms of regulation, and function
48. Phospholipase D
49. Mechanism of amyloid beta-peptide (1-42) toxicity in PC 12 cells
50. Choline's phosphorylation in rat striatal slices is regulated by the activity of cholinergic neurons
51. 2 and its role in brain tissue
52. Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalogens
53. 2 activity: Their neurochemical effects and therapeutical importance for neurological disorders
54. Concomitant increases in the levels of choline and free fatty acids in rat brain: Evidence supporting the seizure-induced hydrolysis of phosphatidylcholine
55. Localized proton NMR spectroscopy in different regions of the human brain in vivo. Relaxation times and concentrations of cerebral metabolites
56. The source of choline for acetylcholine synthesis in brain
57. Labeled choline and phosphorylcholine: Body distribution and brain autoradiography
58. Acetylcholine in human CSF: Methodological considerations and levels in dementia of Alzheimer type
59. β-Amyloid increases choline conductance of PC12 cells: Possible mechanism of toxicity in Alzheimer's disease
60. Renal medullary organic osmolytes
61. Free fatty acids in the rat brain in moderate and severe hypoxia
62. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
63. 2 activity in Alzheimer brains
64. Elevated phosphocholine and phosphatidylcholine following rat entorhinal cortex lesions
65. 2
66. The cholinergic system in Alzheimer disease
67. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain
68. Membrane instability, plasmalogen content, and Alzheimer's disease
69. The influence of long-term dietary choline deficiency on choline metabolites in the rat brain
70. Degradation of phospholipid molecular species during experimental cerebral ischemia in rats
71. Activity of phosphatidylethanolamine-N-methyltransferase in brain affected by Alzheimer's disease
72. PET imaging of brain tumor with [methyl-C-11]choline
73. 31P-NMR spectroscopy
74. Regulation of acetylcholine synthesis in nervous tissue
75. Proton magnetic resonance spectroscopy studies on human brain myo-inositol in hypoosmolarity and hepatic encephalography
76. 2 in the human astrocytoma cell line 1321N1
77. 2 from bovine brain cytosol
78. Apoptosis is induced by choline deficiency in fetal brain and in PC12 cells
79. Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: A multicenter pilot study
80. Delayed phospholipid degradation in rat brain after traumatic injury
81. Regional metabolic assessment of human brain during development by proton magnetic resonance spectroscopy in vivo and by high-performance liquid chromatography/gas chromatography in autopsy tissue
82. 2 and 6-keto-PGF (1α) in rat CA1 hippocampus during transient cerebral ischemia
83. Relations between the extracellular concentrations of choline and acetylcholine in rat striatum
84. Polyphosphoinositides as a probable source of brain free fatty acids accumulated at the onset of ischemia
85. The toxicity in vitro of β-amyloid protein
86. Seizures increase acetylcholine and choline concentrations in rat brain regions
87. Reduced phospholipase D activity in brain tissue samples from Alzheimer's disease patients
88. Alterations of selected enzymes of phospholipid metabolism in Alzheimer's disease brain tissue as compared to non-Alzheimer's demented controls
89. Phospholipases as mediators of amyloid beta peptide neurotoxicity: An early event contributing to neurodegeneration characteristic of Alzheimer's disease
90. Inhibition of the early phase of free fatty acid liberation during cerebral ischemia by excitatory amino acid antagonist administered by microdialysis
91. 2 and C activation during ischemia
92. Eukaryotic phospholipid biosynthesis
93. 2 in brain cortical cultures
94. Uptake and metabolism of choline by rat brain after acute choline administration
95. Free choline and choline metabolites in rat brain and body fluids: Sensitive determination and implications for choline supply to the brain
96. 2 but not from phospholipase D
97. Role of phospholipase D in nervous system physiology and pathophysiology
98. Phospholipid breakdown and choline release under hypoxic conditions: Inhibition by bilobalide, a constituent of Ginkgo biloba
99. Glutamatergic activation of hippocampal phospholipase D: Postnatal fading and receptor desensitization
100. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain
101. Aggregation of β-amyloid peptide is promoted by membrane phospholipid metabolites elevated in Alzheimer's disease brain
102. Metabolic alterations in postmortem Alzheimer's disease brain are exaggerated by Apo-E4
103. Enhancement of free fatty acid incorporation into phospholipids by choline plus cytidine
104. Acetylcholine release and choline availablity in rat hippocampus: Effects of exogenous choline and nicotinamide
105. Changes in brain energy metabolism, neurotransmitters, and choline during and after incomplete cerebral ischemia in spontaneously hypertensive rats
106. 2)
107. Calcium in ischemic cell death
108. 1H NMR spectroscopy in vivo
109. Output, tissue levels, and synthesis of acetylcholine during and after transient forebrain ischemia in the rat
110. Treatment of Alzheimer's disease with cholinergic drugs
111. Phospholipids in human cerebrospinal fluid
112. Alterations in phosphatidylcholine metabolism of stretch-injured cultured rat astrocytes
113. 2
114. The diversity of volume-regulatory mechanisms
115. 2 in rat brain after severe forebrain ischemia and in endotoxic shock
116. N-methyl-D-aspartate-evoked release of cyclooxygenase products in rabbit hippocampus: An in vivo microdialysis study
117. Activation of N-methyl-D-aspartate-sensitive receptors stimulates arachidonic acid release in primary cultures of cerebellar granule cells
118. N-methyl-D-aspartate-sensitive glutamate receptors induce calcium-mediated arachidonic acid release in primary cultures of cerebellar granule cells
119. Phospholipase D-catalyzed hydrolysis of phosphatidylcholine provides the choline precursor for acetylcholine synthesis in a human neuronal cell line
120. 2 by amyloid-beta peptides in vitro
121. 2
122. Signalling sphingomyelinases: Which, where, how and why?
123. High-performance liquid chromatography of water-soluble choline metabolites
124. Release of acetylcholine in the isolated heart
125. Evidence that 5'-cytidinephosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels
126. Alk-1-enylacyl, alkylacyl, and diacyl subclasses of native ethanolamine and choline glycerophospholipids can be quantified directly by phosphorus-31 NMR in solution
127. Cerebrospinal fluid choline levels are decreased in Parkinson's disease
128. Modification of ion homeostasis by lipid peroxidation: Roles in neuronal degeneration and adaptive plasticity
129. Cholinergic neurotransmission studied in vivo using positron emission tomography or single photon emission computerized tomography
130. 31P NMR of extracted phospholipids
131. + patients
132. 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease
133. Absolute concentrations of metabolites in the adult human brain in vivo: Quantification of localized proton MR spectra
134. 2
135. Differences in red blood cell choline and lipid-bound choline between patients with Alzheimer disease and control subjects
136. Alzheimer disease - Depiction of increased cerebral myo-inositol with proton MR spectroscopy
137. Age-dependent accumulation of phosphatidylcholine hydroperoxide in the brain and liver of the rat
138. Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease
139. 2, prostaglandin F(2α), cyclic AMP, and ATP
140. Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4
141. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET
142. Brain ischemia decreases phosphatidylcholine-phospholipase D but not phosphatidylinositol-phospholipase C in rats
143. Evidence for a membrane defect in Alzheimer disease brain
144. Phospholipid metabolite levels are altered in cerebral cortex of patients with dominantly inherited olivopontocerebellar atrophy
145. Changes in brain organic osmolytes in experimental cerebral ischemia
146. 2-evoked destabilization of planar lipid membranes
147. Phosphoinositide signalling in human brain
148. Changes of the phosphatidylcholine content and the number of synaptic vesicles in relation to the neurohumoral transmission in sympathetic ganglia
149. Multicentre study of 1-α-glyceryl-phosphorylcholine vs. ST200 among patients with probable senile dementia of Alzheimer's type
150. 1H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age associated memory impairment, and probable Alzheimer's disease
151. Eicosanoid production in the caudate nucleus and dorsal hippocampus after forebrain ischemia: A microdialysis study
152. Release of arachidonic acid by NMDA-receptor activation in the rat hippocampus
153. 31P nuclear magnetic resonance study of the brain in Alzheimer's disease
154. Correlation of phosphorus-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease
155. Changes in brain energy and phospholipid metabolism during development and aging in the Fischer 344 rat
156. Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study
157. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia
158. In vivo brain concentrations of N-acetyl compounds, creatine, and choline in Alzheimer disease
159. Cerebroprotective action of the phospholipase inhibitor quinacrine in the ischemia/reperfused gerbil hippocampus
160. Apolipoprotein E4, cholinergic integrity and the pharmaco genetics of Alzheimer's disease
161. Measurement of choline and choline metabolite concentrations using high-pressure liquid chromatography and gas chromatography-mass spectrometry
162. Influx of a choline analog to dog brain measured by positron emission tomography
163. Brain cortical fatty acids and phospholipids during and following complete and severe incomplete ischemia
164. In vivo, ex vivo, and in vitro one- and two-dimensional nuclear magnetic resonance spectroscopy of an intracerebral glioma in rat brain: Assignment of resonances
165. Basal ganglia choline levels in depression and response to fiuoxetin treatment: An in vivo proton magnetic resonance spectroscopy study
166. 2) activity in gerbil brain: Enhanced activities of cytosolic, mitochondrial, and microsomal forms after ischemia and reperfusion
167. In vivo magnetic resonance spectroscopy of human brain: The biophysical basis of dementia
168. Multiple forms of the enzyme glycerophosphodiesterase are present in human brain
169. 2 activity
170. Excitotoxicity and the NMDA receptor: Still lethal after eight years
171. Hydrogen peroxide enhances signal-responsive arachidonic acid release from neurons: Role of mitogen-activated protein kinase
172. 2 and cyclooxygenase-2 in the hippocampus after kainate lesions
173. Exposure to N-methyl-D-aspartate increases release of arachidonic acid in primary cultures of rat hippocampal neurons and not in astrocytes
174. Focal ischemia enhances choline output and decreases acetylcholine output from rat cerebral cortex
175. Effects of middle cerebral artery occlusion on cerebral cortex choline and acetylcholine in rats
176. Effects of hypoxia on choline exchange among organs
177. Domain formation induced by lipid-ion and lipid-peptide interactions
178. MR image-guided P-31 MR spectroscopy in the evaluation of brain tumor treatment
179. 2 is activated after experimental closed head injury in the rat
180. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects
181. 31P magnetic resonance spectroscopy in Alzheimer's and Pick's disease
182. Lipid compositions of different regions of the human brain during aging
183. Fatty acid composition of brain phospholipids in aging and Alzheimer's disease
184. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type
185. Citicholine improves verbal memory in aging
186. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy
187. Choline content of rat brain
188. 2
189. 2) is expressed in human brain astrocytes
190. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains
191. Sympathetic neurons expressing cholinergic properties are poised to allocate choline symmetrically between acetylcholine and the phosphatidylcholine-generating pathway in growing neurites
192. Ischemia-induced changes in cerebral mitochondrial free fatty acids, phospholipids, and respiration in the rat
193. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II)
194. Membrane lipids of adult human brain: Lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years
195. Lack of effect of oral choline supplement on the concentrations of choline metabolites in human brain
196. Cholinomimetic treatment of Alzheimer's disease
197. 2 gene family in mammals
198. Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia
199. Brain choline-containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex
200. Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation
201. Short-term control of the synthesis of acetylcholine
202. Prevention by choline of the depletion of membrane phosphatidylcholine by a cholineesterase inhibitor
203. Choline increases acetylcholine release and protects against stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum
204. 2 and C on free fatty acid release during complete ischemia in rat neocortex
205. 1H NMR spectroscopy in vivo and in vitro
206. 2: A monolayer study
207. Neurodegeneration induced by reverse microdialysis of NMDA: A quantitative model for excitotoxicity in vivo
208. Free fatty acid and diacylglycerol accumulation in the rat brain during recurrent seizures is related to cortical oxygenation
209. 3H]arachidonic acid release in cerebellar granule cells
210. Modulation of neuronal phospholipase D activity under depolarizing conditions
211. Influence of dietary choline availability and neuronal demand on acetylcholine synthesis by rat brain
212. Choline utilization by central cholinergic neurons
213. 2 activation and phospholipid breakdown in rat hippocampus
214. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicholine
215. Neural membrane phospholipids in Alzheimer disease
216. Alteration of intracellular metabolite diffusion in rat brain in vivo during ischemia and reperfusion
217. Glucose regulates glutamate-evoked arachidonic acid release from cultured striatal neurons
218. 2 in tumor necrosis factor-induced apoptosis
219. 2
220. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons
221. 'Autocannibalism' of choline-containing membrane phospholipids in the pathogenesis of Alzheimer's disease - A hypothesis
222. 2 by cyanide in PC12 cells
223. 2 from rat brain
224. Phospholipid-derived choline intermediates and acetylcholine synthesis in mouse brain synaptosomes
225. Accumulation of glycerophosphocholine (GPC) by renal cells: Osmotic regulation of GPC:choline phosphodiesterase
226. Region-specific and calcium-dependent increase in dialysate choline levels by NMDA
227. Dietary choline: Biochemistry, physiology, and pharmacology
228. Formation of unesterified choline by rat brain
229. Choline phospholipids: Signal transduction and carcinogenesis
230. Choline and human nutrition
231. Free fatty acids, neutral glycerides, and phosphoglycerides in transient focal cerebral ischemia